US lawmakers blast patent thickets in letter to USPTO director

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

US lawmakers blast patent thickets in letter to USPTO director

retro banner with red vintage typewriter with a blank sheet of p

Three Republican and two Democratic Congress members have claimed that patent thickets hinder access to affordable medicine

Members from both sides of the US House of Representatives wrote to USPTO director Kathi Vidal on Friday, March 24, expressing their concern about “patent thicketing.”

Five members – three Republicans and two Democrats – urged Vidal to consider implementing the proposed policies outlined in her October 4 2022 request for comment.

Vidal’s suggested that parties seeking to overcome rejections based on obvious variations of prior claims should stipulate that those claims aren’t patentably distinct.

Such admission would ensure that if one of the duplicates was invalidated, courts could consider that fact as evidence against the others, the members claimed.

“Branded manufacturers will often seek numerous patents on a single feature of a drug, creating a dense web, or thicket, of patents that delay generic and biosimilar competition,” the letter said.

“While some may question the quality of these patents, the high cost, uncertainty, and lengthy process for challenging them, makes it practically impossible to sort the good from the bad.”

The letter added that patent thickets, the process of seeking multiple patents on a single feature of drug, protected older drugs from competition, which costs the US government and taxpayers more money and hinders patients’ options for cost-effective treatment.

The signees were Republican Jodey Arrington, Michael Burgess and Darrell Issa, and Democrats Lloyd Doggett and Annie Kuster.

Vidal’s October 2022 request for comment came about after President Joe Biden issued an executive order to promote access to drugs in 2021 and after six senators raised concerns about patent thickets in a June 2022 letter to the USPTO.

more from across site and SHARED ros bottom lb

More from across our site

The LMG Life Sciences Americas Awards is thrilled to present the 2025 shortlist
A new order has brought the total security awarded to a Canadian tech company to $45 million, the highest-ever by an Indian court in an IP case
Andrew Blattman reflects on how IP practices have changed and shares his hopes for increased AI use and better performance on the stock market
The firm said major IP developments included advising on a ‘landmark’ deal involving green hydrogen production, as well as two major acquisitions
The appointments follow other recent moves in the European market as firms look to bolster their UPC offerings
Deborah Kirk discusses why IP and technology have become central pillars in transactions and explains why clients need practically minded lawyers
IP STARS, Managing IP’s accreditation title, reveals its latest rankings for patent work, including which firms are moving up
Leaders at US law firms explain what attorneys can learn from AI cases involving Meta and Anthropic, and why the outcomes could guide litigation strategies
Attorneys reveal the trademark and copyright trends they’ve noticed within the first half of 2025
Senior leaders at TE Connectivity and Clarivate explain how they see the future of innovation
Gift this article